Michael Rabinovitch, Sr Vice President & Controller of Office Depot, Inc. (ODP) Just Sold Shares; Syndax Pharmaceuticals (SNDX) Sellers Increased By 44.97% Their Shorts

Syndax Pharmaceuticals Incorporated (NASDAQ:SNDX) had an increase of 44.97% in short interest. SNDX’s SI was 1.00M shares in January as released by FINRA. Its up 44.97% from 693,200 shares previously. With 345,200 avg volume, 3 days are for Syndax Pharmaceuticals Incorporated (NASDAQ:SNDX)’s short sellers to cover SNDX’s short positions. The SI to Syndax Pharmaceuticals Incorporated’s float is 8.14%. The stock increased 5.35% or $0.48 during the last trading session, reaching $9.46. About 320,300 shares traded or 43.16% up from the average. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has risen 7.09% since January 10, 2017 and is uptrending. It has underperformed by 9.61% the S&P500.

The Sr Vice President & Controller of Office Depot Inc, Michael Rabinovitch, has just unloaded – 1,352 shares of the company he’s leading – coming to an aggregate sell of $4,637 U.S. Dollars (this based on share price of $3.4). Michael Rabinovitch currently owns 83,839 shares or 0.02% of Office Depot Inc’s market cap. This sudden trade was finished on January 9, 2018 and is ready for use on the Security Exchange Commission’s website.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company has market cap of $230.73 million. The companyÂ’s lead product candidate is Entinostat, which is in Phase III clinical trial for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer; and Phase 2b clinical trial. It currently has negative earnings. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity.

Office Depot, Inc., together with its subsidiaries, supplies office services and products in North America. The company has market cap of $1.73 billion. The firm operates in two divisions, North American Retail and North American Business Solutions. It has a 5.66 P/E ratio. It offers office supplies, technology products and solutions, business machines and related supplies, facilities products, and office furniture, as well as copy and print services.

The stock decreased 1.47% or $0.05 during the last trading session, reaching $3.35. About 6.33M shares traded or 28.51% up from the average. Office Depot, Inc. (NASDAQ:ODP) has risen 51.05% since January 10, 2017 and is uptrending. It has outperformed by 34.35% the S&P500.

Among 12 analysts covering Office Depot (NASDAQ:ODP), 3 have Buy rating, 3 Sell and 6 Hold. Therefore 25% are positive. Office Depot has $11.0 highest and $3.10 lowest target. $5.96’s average target is 77.91% above currents $3.35 stock price. Office Depot had 21 analyst reports since September 8, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, December 11 by Bank of America. The stock has “Buy” rating by Bank of America on Tuesday, September 5. The rating was maintained by Jefferies on Wednesday, October 4 with “Hold”. Telsey Advisory Group maintained it with “Market Perform” rating and $4.50 target in Friday, October 28 report. The rating was maintained by Credit Suisse on Monday, March 7 with “Outperform”. The stock of Office Depot, Inc. (NASDAQ:ODP) earned “Hold” rating by Jefferies on Wednesday, June 14. The firm earned “Hold” rating on Thursday, September 28 by Jefferies. The stock has “Sell” rating by J.P. Morgan on Monday, October 30. The stock of Office Depot, Inc. (NASDAQ:ODP) earned “Sell” rating by UBS on Thursday, August 4. The stock has “Hold” rating by Loop Capital on Tuesday, December 13.

Analysts await Office Depot, Inc. (NASDAQ:ODP) to report earnings on March, 7. They expect $0.08 earnings per share, down 27.27% or $0.03 from last year’s $0.11 per share. ODP’s profit will be $41.29M for 10.47 P/E if the $0.08 EPS becomes a reality. After $0.14 actual earnings per share reported by Office Depot, Inc. for the previous quarter, Wall Street now forecasts -42.86% negative EPS growth.